Notably, pharmacological targeting of CRABP2 using SNIPER-11 reduces cholesterol content, suppresses AKT activation, and sensitises tumours to gemcitabine both in vitro and in patient-derived xenograft models [65]. This evidence concerns the gene CRABP2 and neoplasm.